Murine dendritic cell rapamycin-resistant and rictor-independent mTOR controls IL-10, B7-H1, and regulatory T-cell

Brian R Rosborough1, Dàlia Raïch-Regué, Benjamin M Matta

  • 1Thomas E. Starzl Transplantation Institute, Department of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.

Blood
|February 28, 2013
PubMed

Insights

Rapamycin-sensitive mTORC1 promotes effector T cells, while a rapamycin-insensitive mTOR pathway restrains regulatory T cell induction. This reveals a novel mTOR mechanism impacting immune responses.

Area of Science:

  • Immunology
  • Molecular Biology
  • Cell Biology

Background:

  • Mammalian target of rapamycin (mTOR) is a critical kinase regulating immune cell function.
  • mTOR operates in two complexes, mTORC1 and mTORC2, with distinct roles.
  • Rapamycin (RAPA) selectively inhibits mTORC1, paradoxically reducing IL-10 and B7-H1 in dendritic cells (DCs).

Purpose of the Study:

  • To elucidate the mechanism behind RAPA's paradoxical effects on IL-10 and B7-H1 expression in DCs.
  • To investigate the role of RAPA-insensitive mTOR pathways in DC-mediated immune regulation.
  • To define the distinct roles of RAPA-sensitive and RAPA-insensitive mTOR signaling in T cell differentiation.

Main Methods:

  • Utilized catalytic mTOR inhibitors.
  • Employed dendritic cells genetically modified to lack mTORC2.
  • Analyzed signal transducer and activator of transcription 3 (STAT3)-mediated gene expression.
  • Assessed the induction of regulatory T cells (Tregs) by DCs.

Main Results:

  • Identified a RAPA-insensitive and mTORC2-independent mTOR mechanism controlling IL-10 and B7-H1 expression during DC maturation.
  • Demonstrated that catalytic mTOR inhibition promotes B7-H1-dependent and IL-1β-dependent Treg induction by DCs.
  • Established that RAPA-sensitive mTORC1 promotes effector T cell expansion, while RAPA-insensitive mTORC1 restrains Treg induction.

Conclusions:

  • Defined a novel immunoregulatory pathway involving distinct mTORC1 activities.
  • Characterized the first known RAPA-insensitive mTOR pathway not solely mediated by mTORC2.
  • Highlighted implications for using catalytic mTOR inhibitors in treating inflammatory diseases.

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
T Cell Types and Functions01:24

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...